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Abstract
Background: Opioid dependence is a major health concern across the world and does also occur in adolescents.
While opioid substitution treatment (OST) has been thoroughly evaluated in adult populations, very few studies
have examined its use in adolescents. There are concerns that OST is underutilised in adolescents with heroin
dependence. We sought to measure changes in drug use among adolescents receiving OST and also to examine
treatment attrition during the first 12 months of this treatment.
Methods: We included all heroin dependent patients aged under 18.5 years commencing OST at one outpatient
multidisciplinary adolescent addiction treatment service in Dublin, Ireland. Psycho-social needs were also addressed
during treatment. Drug use was monitored by twice weekly urine drugs screens (UDS). Change in the proportion of
UDS negative for heroin was examined using the Wilcoxon signed rank test. Attrition was explored via a Cox
Regression multivariate analysis.
Results: OST was commenced by 120 patients (51% female and mean age 17.3 years). Among the 39 patients who
persisted with OST until month 12, heroin abstinence was 21% (95% confidence interval [CI] = 9–36%) at month three and
it was 46% (95% CI = 30–63%) at month 12. Heroin use declined significantly from baseline to month three (p< 0.001) and
from month three to month 12 (p= 0.01). Use of other drugs did not change significantly. People using cocaine during
month 12 were more likely to be also using heroin (p= 0.02). Unplanned exit occurred in 25% patients by 120 days. The
independent predictors of attrition were having children, single parent family of origin, not being in an intimate
relationship with another heroin user and evidence of cocaine use just before treatment entry.
Conclusions: We found that heroin dependent adolescent patients achieved significant reductions in heroin
use within three months of starting OST and this improved further after a year of treatment, about half being
heroin abstinent at that stage. Patient drop out from treatment remains a challenge, as it is in adults. Cocaine
use before and during treatment may be a negative prognostic factor.
Keywords: Adolescents, Heroin dependence, Methadone treatment, Buprenorphine treatment, Treatment adherence
* Correspondence: smythbo@tcd.ie
1Department of Public Health and Primary Care, Trinity College Dublin,
Dublin 2, Ireland
2Graduate Entry Medical School, University of Limerick, Limerick, Ireland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Smyth et al. BMC Pediatrics  (2018) 18:151 
https://doi.org/10.1186/s12887-018-1137-4
Background
There is global ongoing concern regarding opioid depend-
ence. While this is primarily focused on non-prescribed use
of pharmaceutical opioids in USA currently, heroin has been
the main concern elsewhere, including Ireland [1, 2]. The
prevalence of heroin dependence tends to fluctuate over
time and is much more common in adults than adolescents
[1, 3]. In Dublin, heroin use first emerged as a concern
among adolescents in the 1990s, in the midst of a dramatic
increase in heroin dependence among adults [3, 4].
Opioid substitution treatment (OST) is now the main
first line treatment intervention for heroin dependence
among adults [5]. The main medications used are
methadone, a full agonist or buprenorphine, a partial
agonist. There are legislative and administrative obsta-
cles in many jurisdictions to provision of OST to adoles-
cents [1]. The limited evidence base for this treatment in
this younger age range is also an issue which may be
contributing to wariness by clinicians to prescribe [2, 6].
A recent study in USA found that just 2.4% of adoles-
cents attending treatment for heroin use received
medication [1].
There are no clinical trials examining outcome of OST
beyond three months in people aged under 18 years old
[6]. There are a small number of ‘open label’ longer
term studies. The largest study has involved just 153 pa-
tients and was conducted over 40 years ago [7]. How-
ever, it provided no information on cessation of heroin
use among those who remained on methadone treat-
ment (MT), and the dose of methadone was limited to
just 20mgs so its implications for modern practice are very
unclear. Although the primary goal of OST is to assist the
patient in reducing their heroin use, the other adolescent
studies also fail to provide any firm information on this
issue. The absence of scientific information on the rates of
ongoing heroin use by adolescents on OST acts as an obs-
tacle to provision of this treatment [2].
The DARP study of adolescents in USA in the 1970s did
report a progressive decline in heroin use over the first
year of MT but it did not provide any specific information
on the actual rates of heroin use during treatment [8].
More recently, the NIDA multisite buprenorphine/nalox-
one treatment (BT) trial examined treatment of youth
over a three month period, although only 12 participants
were under eighteen years-old. At week eight, 77% of
those retained on BT provided an opiate negative urine
drug screen [9]. Abstinence from heroin at the end of that
trial was associated with greater baseline medical and psy-
chiatric problems, a history of recent injecting and evi-
dence of early cessation of heroin use during BT [10].
Adolescents entering addiction treatment typically
present with polysubstance use and this is also the case for
those with primary dependence upon heroin [11–13]. An
adolescent’s motivation to address use of one substance
such as heroin may not generalise to other substances [13].
Although there is evidence that adults on OST can also
achieve significant reductions in use of other drugs, there is
no such evidence for OST programs for adolescents [14].
The DARP study from the USA in the 1970s reported evi-
dence of increased use of cannabis and alcohol among
youth on OSTat follow up [8].
Drop out from OST has been examined by a small
number of studies in this age range. Studies of MT indi-
cate that 25% of patients drop out within approximately
four months [7, 8, 15]. Bell & Mutch found that the drop
out from BT was significantly greater than from MT
[16]. Other studies of BT in this age range also indicate
frequent early drop out from treatment, with typically a
quarter of patients exiting within 4 to 8 weeks [17–19].
Given this paucity of outcome studies of OST in adoles-
cent heroin dependence, we sought to address a number
of questions which are of importance to clinicians and pa-
tients in order to make informed decisions. What propor-
tion of adolescents ceases heroin use while on OST? Does
abstinence increase incrementally or simply stabilise be-
yond three months on OST? What is the rate of drop out?
Are there any baseline or treatment characteristics which
are associated with either abstinence or drop out?
Methods
Setting, assessment and treatment
This study was based at the Young Persons’ Programme
(YPP) within the National Drug Treatment Centre
(NDTC) in Dublin, Ireland. The approach to assessment
and treatment of heroin dependent adolescents at this
service is summarised below but has been described in
detail elsewhere [20, 21]. Although published a number
of years after the establishment of the YPP, the approach
to treatment is consistent with the UK guidance on
pharmacological management of substance dependence
among young people [22].
Assessment typically involved three clinic visits to
meet different members of the multi-disciplinary team, a
supervised urine drug screen (UDS) being obtained at
each visit. In addition to assessing for heroin depend-
ence using ICD-10 criteria, co-existing psychological, de-
velopmental, social and physical needs were identified.
The main pillars of treatment involved OST (methadone
or buprenorphine), counselling and in some cases, family
therapy. Induction onto a stable dose of methadone typic-
ally occurred over a period of about two weeks while
buprenorphine induction took 2–3 days [23]. If patients
continued to use heroin or resumed use after a period of
abstinence, an increase in medication was considered. Use
of other substances was also addressed during treatment.
Where the initial opioid agonist medication was associated
with a poor treatment response, the patient was offered
the option of switching to the alternative.
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Patients provided two supervised UDS per week for
on-site drug toxicology testing during treatment. These
samples were screened for opiates, EDDP (a methadone
metabolite), cocaine, benzodiazepines and alcohol. They
were intermittently screened for amphetamines and can-
nabis. The provision of ‘take-away’ doses of medication
was utilised as a contingent reinforcer of drug abstin-
ence, as evidenced by urine toxicology.
Patients were also provided with treatment of co-
morbid medical or psychiatric problems [21]. They were
actively supported in addressing co-existing housing, vo-
cational and criminal justice related needs as part of
their care plan.
The overarching goal of the service was to reduce the
harm which young people were experiencing related to
their drug use. It held an aspiration, but not an insist-
ence, that patients progress towards complete abstinence
via gradual OST dose reduction and ultimate cessation
of this medication. This ultimately occurs in about one
in every four cases [20]. Where dose tapering occurred,
it was generally conducted slowly on an outpatient basis
over a period of about three months, negotiated with the
individual patient.
Patients
The inclusion criteria were:- heroin dependence, aged
under 18.5 years and commenced OST. The cohort
under study included patients who commenced treat-
ment between May 2000 and June 2016. Patients with a
primary diagnosis of dependence on prescription opioids
were excluded, as such patients have been rarely en-
countered in Ireland.
Data collection
The study was approved by the Research Ethics Com-
mittee of the NDTC. Baseline descriptive characteristics
were obtained from the patients’ initial structured as-
sessment, this being adapted from the Maudsley Addic-
tion Profile [24]. We recorded information on patient
treatment participation at three, six and twelve months.
If a patient was not attending the service on these dates,
we noted the date of and reason for exit.
Those who were referred to and commenced on an-
other OST program were categorised as “transfers for
ongoing treatment”. This typically involved transfer to
an adult OST program, this option being available to pa-
tients after their 18th birthday. However, most opted to
persist with treatment on the YPP beyond this age [20].
Patients were categorised as exiting via “dose taper” if
they adhered to the prescribed dose reduction regime
and showed urinalysis evidence of heroin abstinence at
discharge from the treatment program. Patients who
ended treatment because they were incarcerated were
categorised as exiting due to “prison”. Finally, patients
who simply stopped attending, relocated without arran-
ging alternative treatment or left treatment prematurely
against medical advice were all categorised as being
“drop outs”. Patients were generally not deemed to have
dropped out of their index treatment episode unless that
had failed to attend for four weeks. If they were deemed
a drop out, then the date of last attendance for medica-
tion was recorded as the date of discharge. Although
many patients re-entered treatment after dropping out
or following a relapse to heroin use after a successfully
completed dose taper, only their first or index treatment
episode was included for the purposes of this study. The
pattern of transitions out of and back into treatment
have been described in a separate study [20]. If a patient
switched from BT to MT or vice versa, but continued in
treatment, this was not viewed as a treatment exit.
To examine changes in drug use, five periods during
the first year of treatment contact were examined for
each patient. The results of all urine drug screens (UDS)
provided by each patient during each period was col-
lated. The periods in question were (a) pre treatment as-
sessment phase which was typically 7 to 10 days in
duration and involved provision of 2–4 UDS, (b) induc-
tion phase which comprised the remaining days in that
first month of patient contact after commencing OST,
(c) third entire month of treatment, (d) sixth entire
month of treatment and (e) twelfth entire month of
treatment. During phases (b) to (e), patients were typic-
ally providing two UDS per week. For each patient, a di-
chotomous outcome variable to indicate abstinence/use
was created for each of the phases they were being
treated (a) to (e). They were deemed to be using heroin
if any one UDS sample tested positive for opiates during
that phase. If all UDS were opiate negative, they were
deemed heroin abstinent. Similarly, a single positive for
cocaine in a month resulted in that month being deemed
one of cocaine use.
Statistics
In order to conduct an exploratory analysis, we used Pear-
son chi square test to examine association between categor-
ical covariates and dichotomous outcome variables of
interest, except in instances where a predicted cell value
was less than five, where Fisher’s Exact test was utilised.
Odds ratios and their 95% confidence intervals were calcu-
lated to indicate the direction and magnitude of associa-
tions. Continuous variables were converted into categorical
variables, by choosing the median value as the point of split,
apart from age where we used 18th birthday as the cut-off.
When reporting the proportion of patients who were
heroin abstinent, we also calculated the 95% confidence
intervals of those rates using the exact confidence limits
for binomial proportions. McNemar’s paired proportions
test with continuity correction was employed to determine
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whether OST was associated with changes in the binary
category of drug use. We sought to confirm that heroin
abstinence in month three was greater than baseline, and
that abstinence at months six and twelve were greater
than month three. We also examined changes in the pro-
portion of samples which tested negative for heroin using
the related samples Wilcoxon signed rank test. For each
period, we calculated this proportion by dividing the num-
ber of negative tests by the total number of UDS obtained.
All of these analyses were confined to the subgroup of pa-
tients who persisted with OST for a full year.
To examine drop out and factors associated with
same, the Kaplan-Meier test was conducted. The event
of interest was unplanned exit from treatment via drop
out or imprisonment. The time to treatment exit, in
days, was recorded for each patient who left their index
treatment episode during the first year, whether by un-
planned exit or via planned exit (following completion
of dose taper or via transfer to another OST service).
For patients who persisted with OST, the number of
days entered was 365 days. The Log Rank was used to
test for the equality of the survival distributions within
each covariate. To facilitate interpretation of these differ-
ences, the estimated number of days to drop out by 25%
is reported. In order to explore independent predictors
of unplanned exit, we then conducted a multivariate
analysis using Cox Regression. Covariates were selected
for entry into the final equation using the forward and
backward selection technique. All analyses were con-
ducted using IBM SPSS Statistics, version 21.
Results
Description of participants
There were 120 eligible patients who commenced OST.
One patient with primary methadone dependence was ex-
cluded and there were no presentations with primary pre-
scription opioid dependence. The patient characteristics
are provided in Table 1. The mean age was 17.3 years
(range 14–18 years). There were 13 (11%) who had not
yet reached their 16th birthday. Eighty-eight per cent were
using heroin daily at treatment entry. Thirty-nine patients
persisted with treatment to month 12 and their profile is
also outlined in Table 1. Twenty-nine (24%) left following
completion of dose taper and nine (8%) were transferred
elsewhere for ongoing OST. There were 43 unplanned
treatment exits, with 36 (30%) dropping out and 7 (6%)
going to prison. There were no deaths during treatment.
Cessation of heroin use and other drugs
Table 2 presents the results of urine drug screens from the
subgroup of patients who persisted with OST for at least
12 months. This table indicates the proportion demon-
strating abstinence from each drug at each time period ex-
amined. During the third month of treatment 8 (21% [95%
confidence interval (CI) = 9–36%]) were abstinent from
heroin. Six (15% [95%CI = 6–31%]) were abstinent from
heroin, cocaine and benzodiazepines. At month 12, there
were 18 (46% [95%CI = 30–63%]) abstinent from heroin,
of whom nine (23% [95%CI = 11–39%]) were also abstin-
ent from cocaine and benzodiazepines.
Changes in drug use over time
Table 2 also indicates that heroin abstinence increased
significantly from baseline to three months, from base-
line to twelve months and from third month to twelfth
month. Rates of use of other substances did not change
significantly from baseline. When looking beyond heroin
abstinence to examine changes in the proportions of
negative urine screens, it also emerged that there were
significant reductions in heroin use between baseline
and month 3 and from month 3 to month 12. However,
there was no significant change in heroin use between
months 3 and 6. When comparing the proportions of
heroin negative urine screens between months 3 and 12,
we found that eight (21%) patients deteriorated, six
(15%) were unchanged and 25 (64%) improved.
Correlates of heroin abstinence
There were very few pre-treatment characteristics sig-
nificantly associated with heroin abstinence at month 12.
Full results of this analysis are presented in Add-
itional file 1: Table S1 in an on-line supplement. None of
the patients who had a previous psychiatric admission
were abstinent (p = 0.02). Abstinence was not signifi-
cantly associated with higher medication dose (p = 0.88).
All of the patients who were using cocaine during
month 12 were also using heroin (p = 0.02). Early reduc-
tions in heroin use, as evidenced by provision of at least
one heroin negative sample during induction tended to
be associated with reduced likelihood of heroin abstin-
ence at month 12 (p = 0.07).
We repeated the analysis, with imputed positive heroin
results for the 43 patients who had an unplanned dis-
charge. This indicated that heroin abstinence was signifi-
cantly associated with being in an intimate/sexual
relationship with another heroin user (OR 3.4 [95%CI 1.
1–10.0], p = 0.02). No other baseline characteristic was
significantly associated with abstinence in that analysis
with imputed results.
Persistence with OST
Information on attrition during treatment is reported in
Table 3. Overall, the estimated length of time to 25%
leaving treatment in an unplanned manner was 120
(Standard Error 41) days. The table only presents results
of the covariates where the Log Rank test indicated a p
value of less than 0.2, although all covariates in Table 1
were explored. There was no significant difference
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Table 1 Characteristics of 120 adolescents commencing opioid substitution treatment, and subgroup who persisted in treatment
until month 12
Total Group Missing
data
In treatment until month 12
N (%)c N (%)d OR 95% CI OR P value
Number in Treatment 120 39 (33)
Socio-demographic characteristics
Female 61 (51) 25 (41) 2.0 (0.9–4.4) 0.07
Aged under 18.0 years 104 (87) 35 (34) 1.5 (0.5–5.1) 0.49
Left school under 15 years 51 (46) 8 18 (35) 1.0 (0.5–2.3) 0.92
Not in employment, education or training 81 (70) 4 29 (36) 1.7 (0.7–4.1) 0.24
Two parent family support 59 (50) 1 27 (46) 3.8 (1.6–8.6) 0.001
Has a child 6 (5) 0 (0) n/a 0.18a
Has been in care 38 (32) 2 10 (26) 0.7 (0.3–1.6) 0.35
Sibling Heroin Use 45 (39) 4 17 (38) 1.4 (0.6–3.0) 0.45
Parental heroin Use 25 (22) 4 6 (24) 0.6 (0.2–1.5) 0.25
Partner uses heroin 47 (39) 1 18 (38) 1.5 (0.7–3.3) 0.30
Homeless or hostel in past month 34 (28) 11 (32) 0.9 (0.4–2.2) 0.89
Previous criminal convictions 46 (41) 8 14 (30) 0.9 (0.4–2.0) 0.80
Ever incarcerated 31 (27) 6 8 (26) 0.8 (0.3–1.9) 0.55
Psychiatric History
Ever assessed by a psychiatrist 62 (53) 2 22 (36) 1.4 (0.6–2.9) 0.44
Past Inpatient psychiatric admission 10 (9) 4 6 (60) 3.2 (0.8–12) 0.09a
Past DSH 36 (31) 5 12 (33) 1.1 (0.5–2.5) 0.86
Substance Use
Lifetime Drug Use
Non-prescribed benzodiazepines 107 (90) 1 36 (34) 1.0 (0.3–3.6) 1.0a
Non-prescribed methadone 90 (78) 5 30 (33) 0.8 (0.3–1.9) 0.54
Cocaine use 76 (68) 8 30 (40) 2.7 (1.1–7.0) 0.04
Injected 53 (45) 2 17 (32) 1.0 (0.5–2.2) 0.99
Commenced heroin under 15 years of age 43 (36) 2 20 (47) 2.6 (1.2–5.7) 0.02
Regular heroin use for more than 12 months 73 (64) 6 26 (36) 1.2 (0.5–2.7) 0.67
Past Month Drug Use
Non-prescribed benzodiazepines 71 (60) 1 26 (37) 1.4 (0.6–3.1) 0.40
Non-prescribed methadone 71 (60) 1 27 (38) 1.7 (0.7–3.7) 0.22
Cocaine 31 (26) 2 10 (32) 1.0 (0.4–2.3) 0.91
Cannabis 80 (73) 11 27 (34) 1.3 (0.5–3.4) 0.54
Amphetamine 9 (9) 19 4 (44) 1.9 (0.5–7.7) 0.45a
Alcohol 46 (45) 18 17 (37) 1.2 (0.5–2.8) 0.61
Injecting 35 (29) 1 13 (37) 1.5 (0.7–3.4) 0.34
Using more than 3 ‘bags’ heroin per day 60 (53) 7 18 (30) 0.9 (0.4–2.0) 0.81
Pre-treatment UDSb positives
Benzodiazepines 71 (59) 26 (37) 1.6 (0.7–3.6) 0.25
Methadone 67 (56) 20 (30) 0.8 (0.4–1.6) 0.49
Cocaine 13 (11) 3 (23) 0.6 (0.2–2.3) 0.54a
Cannabis 47 (47) 20 13 (28) 0.7 (0.3–1.6) 0.38
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between those commenced on Buprenorphine or metha-
done (log rank test statistic 1.04, p = 0.31). To further as-
sist understanding of the analysis and the pattern of drop
out, an example is provided in Fig. 1, which contrasts pa-
tients who showed UDS evidence of cocaine use during
assessment against those without such cocaine use.
The Cox regression analysis (see Table 3) indicated
that patients who had no children, grew up in families
with two parents, were in an intimate relationship
with another heroin user and were abstinent from
cocaine in pre-treatment drug screens demonstrated
significantly lower rates of unplanned exit from
treatment.
Of the 20 people commenced on buprenorphine who
persisted with treatment for three months, six (30%) had
switched to methadone at that point. Only one person
(2%) had switched from methadone to buprenorphine by
month three. Seven people who commenced buprenor-
phine remained in treatment for 12 months, by which
time six has switched to methadone. Only two of the 32
commenced on methadone had switched to buprenor-
phine by month 12.
Discussion
Reductions in heroin use and incremental change
Heroin use is associated with a vast array of risks [2, 5, 25].
A key goal of OST is to assist patients in reducing, and
ideally stopping, their use of heroin [25]. Our study indi-
cates that this treatment delivers substantial reductions in
heroin use among adolescents. Almost half of these young
patients who persisted with OST for a year demonstrated
complete cessation of heroin use during their twelfth
month of treatment. Previous studies of OST in adolescent
heroin dependence have largely ignored the issue of abstin-
ence during treatment. In a slightly older cohort, Kellogg et
al. reported that patients who persisted with OST were her-
oin abstinent every other month on average, although urine
drug screens were conducted inconsistently which increases
the possibility that occasional use was not detected in that
study [15].
The rate of heroin abstinence in month twelve consti-
tuted a significant improvement compared to the third
month of treatment, at which point one in five demon-
strated abstinence. This is consistent with one other
study in adolescents and also with research on adult
Table 1 Characteristics of 120 adolescents commencing opioid substitution treatment, and subgroup who persisted in treatment
until month 12 (Continued)
Total Group Missing
data
In treatment until month 12
N (%)c N (%)d OR 95% CI OR P value
Early Treatment
Suboxone Commenced 32 (27) 7 (22) 0.5 (0.2–1.3) 0.13
At least one heroin negative UDS during induction 50 (46) 12 14 (28) 0.6 (0.3–1.4) 0.28
aP value calculated using Fishers Exact Test Statistic as estimated value in cell was less than 5
bUDS = Urine drug screen
cThis column indicates the proportion (%) of the total group showing that characteristic (e.g. 51% of total group are female)
dThis column indicates the proportion (%) of the subgroup with the characteristic who are still in treatment at month 12 (e.g. 25/61 [41%] of the females were still
in treatment at month 12)
Table 2 Evidence of drug use from urine drug screens (UDS), at baseline and during treatment, among 39 patients who persisted
with treatment for 12 months
Month 1 Month 3 Month 6 Month 12 Baseline vs
Month 3
Baseline vs
Month 12
Month 3 vs
Month 6
Month 3 vs
Month 12Pre-treatment
baseline
Induction
phaseb
Median number of UDS
conducted (range)
3 (2–4) 4 (0–7) 7 (2–10) 7 (1–9) 8 (1–11) Related samples Wilcoxon signed rank
test p value
Median % of UDS heroin
negative (interquartile range)
0 (0–0) 0 (0–33) 50 (0–89) 40 (0–100) 87 (33–100) < 0.001 < 0.001 0.86 0.01
All UDS negative during period p value from McNemar test
Heroin 1 (3) 4 (11) 8 (21) 12 (31) 18 (46) 0.04 < 0.001 0.34 0.04
Benzodiazepine 13 (33) 18 (50) 15 (38) 18 (46) 15 (38) 0.77 0.79 0.45 1.0
Cannabisa 19/32 (59) 18/28 (64) 20/37 (54) 16/33 (48) 14/36 (39) 0.69 0.11 1.0 0.29
Cocaine 36 (92) 36 (100) 32 (82) 31 (79) 33 (85) 0.22 0.45 1.0 1.0
Heroin, benzos & cocaine 0 (0) 1 (3) 6 (15) 8 (21) 9 (23) n/a n/a 0.63 0.55
aUrine drug screens were randomly tested for cannabis, which caused information on use to be missing for some patients during each period
bThree patients did not have any urine screens during induction
n/a not applicable
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Table 3 Unplanned treatment exit among 120 heroin dependent adolescents during the first year on opioid substitution
treatment (OST)
Univariate analysisa Multivariate cox regression
Estimated 25% drop out Log
rank
statistic
P value Hazard
ratio
(HR)
(95% CI
of HR)
P value
Days (SE)
Overall 120 (41)
Socio-demographic characteristics
Sex
Female 75 (9)
Male 225 (55) 2.36 0.13
Age
Under 18 years 120 (45)
Aged 18 years 62 (69) 0.14 0.70
Early school leaver
Left Education under age 15 75 (18)
Left school after 15th birthday 197 (69) 1.83 0.18
Family of origin
Has two parents 270 1.0
Single parent/other relative/adopted 75 (19) 8.56 0.003 3.5 (1.7–6.9) 0.001
Own children
Has a child 72 (61) 5.3 (1.9–14.8) 0.001
No children 123 (40) 5.11 0.02 1.0
History of being in social care
Has been in care 75 (28)
Never in social care 155 (41) 3.52 0.06
Parental heroin use
No heroin use by parents 186 (66)
A parent has heroin problems 72 (52) 2.91 0.09
Heroin use by partner
Partner has used heroin 270 (89) 1.0
No partner/No heroin use by partner 86 (19) 3.53 0.06 2.1 (1.1–4.3) 0.03
Accommodation in past month
Homeless or hostel 69 (25)
Stable accommodation 176 (54) 2.40 0.12
Deliberate self harm (DSH)
Has a history of DSH 75 (28) 1.8 (1.0–3.3) 0.07
No history of past DSH 176 (67) 2.21 0.14 1.0
Pre-treatment Drug Use
Lifetime Cocaine
Use 103 (29)
No use 176 (69) 2.99 0.08
Past month non-prescribed methadone use
Self reported Use 197 (29)
No self reported use 73 (23) 3.42 0.07
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patients showing that longer treatment with OST builds
incremental improvements in outcome [8, 14, 15, 26]. In
their NIDA clinical trial, Woody et al. found a rapid re-
turn to heroin use once patients were tapered off their
three months of buprenorphine treatment [9].
The confirmation that adolescents on OST can achieve
substantial reductions in heroin use, with many doing so
very early in treatment, should act as source of optimism
for clinicians. It suggests that it is realistic for staff and
treatment services to have a high expectation of reduced
heroin use early in treatment and to be confident that
many patients will achieve periods of sustained abstin-
ence during treatment.
We found no indication of a relationship between
medication dose and heroin abstinence. There was no
upper ceiling dose used in this service and our finding
may indicate that dose was appropriately titrated against
clinical need. There is research to indicate increased her-
oin use at lower OST doses in both adolescents and
adults [18, 27]. In contrast, Kellogg et al. detected
greater heroin use among young adults on higher
methadone doses [15].
Table 3 Unplanned treatment exit among 120 heroin dependent adolescents during the first year on opioid substitution
treatment (OST) (Continued)
Univariate analysisa Multivariate cox regression
Estimated 25% drop out Log
rank
statistic
P value Hazard
ratio
(HR)
(95% CI
of HR)
P value
Days (SE)
Cocaine
Positive baseline urine drug screen 50 (15) 3.2 (1.4–7.4) 0.006
All baseline urine drug screens negative 176 (55) 3.97 < 0.05 1.0
Quantity of heroin use per day
Using 3 ‘bags’ or more per day 69 (19)
Using less than 3 ‘bags’ day 225 (40) 5.77 0.02
Dose of OST at month threeb
Dose >50mgs methadone (or equivalent) 239 (24)
Dose <= 50mgs methadone (or equivalent) > 365 2.90 0.09
aKaplan Meier Survival analysis. The model estimate of the number of days to unplanned discharge by 25% of patients with that characteristic is reported,
for comparison
bincludes the 72 people being prescribed OST after 90 days, with methadone equivalent dose for those on buprenorphine being multiplied by 5 (i.e. if on 12mgs
of buprenorphine, assigned value of 60mgs in methadone equivalents)
Fig. 1 Unplanned treatment exit by 120 adolescents on OST; impact of cocaine use at treatment entry
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Treatment retention
The second main focus of this study was treatment reten-
tion. We found that one in four patients had an un-
planned treatment exit by 120 days. Retention rates were
similar in DARP in the 1970s and in the more recent
study by Kellogg et al. [8, 15]. Those two studies examined
methadone treatment. A number of studies examining use
of buprenorphine in other settings report much higher
rates of attrition among adolescent patients [16–18]. In
contrast to Bell & Mutch, we found no significant differ-
ence between the two opioid agonist medications, al-
though many patients in our study did switch from
buprenorphine to methadone during treatment [16]. One
factor which complicates comparisons of retention rates
across all of these studies relates to the variable criteria
used to define ‘drop out’. In our study, patients who
recommenced regular attendance after a period of up to
four weeks non-attendance were viewed as still being in
their index treatment episode. Other studies have viewed
patients as having dropped out with much shorter periods
of non-attendance.
Use of other substances
Unfortunately, half of those who were heroin abstinent
demonstrated some ongoing use of benzodiazepines.
Overall, the rates of abstinence from drugs other than
heroin did not increase significantly from pre-treatment
levels. Studies of OST in adults suggest that they can
achieve reductions in use of other drugs [14, 26]. How-
ever, previous research on younger cohorts has also
failed to demonstrate reductions in use of other drugs
and the DARP study found some evidence of increased
use of cannabis and alcohol at follow-up [8, 15].
At this service, efforts were made to address cocaine
use. Where use occurred it was discussed in counselling
sessions and also during key working interventions. Our
failure to successfully reduce cocaine use appears im-
portant for this patient group. Although cocaine use was
not extensive among these heroin dependent adoles-
cents, it seems to act as a negative prognostic factor for
those who use it. Cocaine use at baseline was a signifi-
cant predictor of treatment drop out. Cocaine use during
OST was correlated with ongoing heroin use. A correl-
ation between persistent heroin use and cocaine use has
also been demonstrated by others in both adolescents
and adults [15, 27, 28]. The adverse association between
cocaine use and poorer treatment adherence was also re-
ported by Kellogg et al. [15]. Adult studies of OST have
made similar observations [29, 30]. For these reasons, ef-
forts have been made in Ireland to implement interven-
tions targeting cocaine use among adults attending OST.
The results have been quite disappointing to date, with
poor uptake of counselling treatments being a key obs-
tacle [31]. With polydrug using adolescents, it has been
shown in Ireland and elsewhere that their motivation to
address their main drug may be very different to their
motivation to address substances which they perceive as
quite secondary [13]. In spite of these challenges, ser-
vices working with heroin dependent adolescents should
have protocols in place to assess and respond to use of
cocaine and other substances.
Association of systemic factors with outcome
Other potential prognostic factors were identified in the
exploratory analysis, many of which suggested the im-
portance of the family and social support system around
the adolescent. Some characteristics of family systems
may provide support to an adolescent who is facing a se-
vere drug use disorder while other family types may add
to the strain on an adolescent who is already coping
poorly [32, 33]. Our finding of increased abstinence
when analysis included imputed data, and of better
treatment retention, in those with a heroin using sexual
partner was unexpected. The general view in addiction
treatment is that increased social ties with other drug
users brings poorer outcome [33]. Interestingly, in a sep-
arate study examining outcome after inpatient detoxifi-
cation of heroin dependent adults in Ireland, it also
emerged that being in a relationship with another heroin
user was associated with better outcome [34]. Although
these findings are counter-intuitive, the issue may war-
rant further exploration by other researchers. We have
previously reported that female patients are much more
likely to be in an intimate relationship with another her-
oin user [13]. Typically partners enter treatment at the
same time. It seems possible that a shared goal and a
shared understanding of the challenges faced by a part-
ner may support rather than undermine recovery [35].
We found that adolescents from families with two par-
ents had better retention. Crome et al. also found better
outcome with increased family support [36]. Involve-
ment of parents in both assessment and treatment was
prioritised by the service [21]. Efforts were made to ac-
tively include parents in the care plan. Family involve-
ment in adolescent addiction treatment has been shown
to improve outcomes [37]. It may be the case that fam-
ilies which include two parents are better able to cope
with the strain which addiction places upon the family
system, and therefore better positioned to provide sup-
port to their son or daughter [32].
A final systemic factor which was correlated with out-
come was being a young parent. While only a small
number of these adolescent patients had a child them-
selves, those who were faced with this additional strain
on their personal resources were less likely to persist
with treatment. Drop out occurred in spite of the efforts
by the service to support these young parents via
provision of crèche facilities on site. Others have
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highlighted the particular challenges faced by single par-
ents with addiction issues, and some services have devel-
oped targeted programs of support such as the Parents
under Pressure intervention [38].
Those who had a previous psychiatric admission ap-
peared less likely to be abstinent. Crome et al. also re-
ported poorer outcome in those with a psychiatric
history [36]. However, Subramaniam et al. found that
greater baseline psychiatric problems was associated
with better outcome in the NIDA clinical trial of bupre-
norphine [10]. Our previous research has indicated that
there are improvements in mental health symptoms
among the adolescents attending OST at this service and
lower depressive symptoms correlate with reduced
heroin use [21].
Strengths and limitations
The strengths of this study include the sample size
which is quite large relative to other studies of OST
in this age range. However, the sample size is still
relatively small for statistical purposes, with limited
power. In view of the large number of statistical tests
conducted in this study, and the decision not to alter
the p value via a Bonferoni correction, this raises the
possibility that some significant findings may also
constitute type 1 statistical errors.
The treatment intervention was delivered at a single
site making it easier for clinicians elsewhere to deter-
mine how applicable our findings may be to their
own treatment setting. The monitoring of drug use
by twice weekly supervised UDS constitutes a very
thorough level of evaluation of drug use and we can
be reasonably confident that the patients whom we
determined to be abstinent are truly abstinent. A
limitation can arise from assessing change via very
regular urine screens. For example, a patient could
change from injecting heroin four times a day at
treatment entry to smoking heroin just twice a week.
While this constitutes a very positive achievement
from a harm reduction perspective, all UDS would be
likely to remain opiate positive and our results would
indicate no change in such a scenario.
Conclusions
This study adds to the currently limited evidence base
for OST in adolescents who are heroin dependent. The
positive outcomes appear broadly similar to those
achieved in adults, among whom there is widespread ac-
ceptance of this treatment. One of the lingering doubts
about OST in adolescents since the DARP study relates
to the limited success in achieving reductions in use of
other drugs [8]. In spite of our efforts to address this
use, we also found that levels of use of other substances
remained stubbornly elevated. This does not negate the
fact that the reductions in heroin use were substantial.
Importantly, abstinence increased significantly from
month three to one year, with half of the patient group
on OST having ceased heroin use during their full
twelfth month of treatment. It seems difficult to predict
which patients are going to persist with this treatment
and to have better outcomes. However, use of cocaine,
both prior to and during treatment, appears to be a
negative prognostic factor. With adolescent patients it
appears to be particularly important to be mindful of po-
tential systemic factors which may either support or
undermine treatment success.
Overall, the efforts currently being made to ensure
greater provision of OST to adolescents by groups such
as the American Academy of Pediatrics appear appropri-
ate and timely [2]. Also, where treatment is commenced,
we echo the view of Woody et al. that “clinicians should
be in no hurry to stop an effective medication simply be-
cause the patient is young” [9].
Additional file
Additional file 1: Table S1. Heroin abstinence during month 12 among
39 heroin dependent adolescents on opioid agonist treatment. (DOCX 19 kb)
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